425 related articles for article (PubMed ID: 34075338)
1. Structural insights and inhibition mechanism of TMPRSS2 by experimentally known inhibitors Camostat mesylate, Nafamostat and Bromhexine hydrochloride to control SARS-coronavirus-2: A molecular modeling approach.
Sonawane KD; Barale SS; Dhanavade MJ; Waghmare SR; Nadaf NH; Kamble SA; Mohammed AA; Makandar AM; Fandilolu PM; Dound AS; Naik NM; More VB
Inform Med Unlocked; 2021; 24():100597. PubMed ID: 34075338
[TBL] [Abstract][Full Text] [Related]
2. The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.
Li K; Meyerholz DK; Bartlett JA; McCray PB
mBio; 2021 Aug; 12(4):e0097021. PubMed ID: 34340553
[TBL] [Abstract][Full Text] [Related]
3. Spontaneous binding of potential COVID-19 drugs (Camostat and Nafamostat) to human serine protease TMPRSS2.
Zhu H; Du W; Song M; Liu Q; Herrmann A; Huang Q
Comput Struct Biotechnol J; 2021; 19():467-476. PubMed ID: 33505639
[TBL] [Abstract][Full Text] [Related]
4. Targeting mechanism for SARS-CoV-2
Zhao X; Luo S; Huang K; Xiong D; Zhang JZH; Duan L
Nanoscale; 2021 Nov; 13(45):19218-19237. PubMed ID: 34787160
[TBL] [Abstract][Full Text] [Related]
5. Semi-Mechanistic Pharmacokinetic-Pharmacodynamic Model of Camostat Mesylate-Predicted Efficacy against SARS-CoV-2 in COVID-19.
Kosinsky Y; Peskov K; Stanski DR; Wetmore D; Vinetz J
Microbiol Spectr; 2022 Apr; 10(2):e0216721. PubMed ID: 35412356
[TBL] [Abstract][Full Text] [Related]
6. Synergistic Block of SARS-CoV-2 Infection by Combined Drug Inhibition of the Host Entry Factors PIKfyve Kinase and TMPRSS2 Protease.
Kreutzberger AJB; Sanyal A; Ojha R; Pyle JD; Vapalahti O; Balistreri G; Kirchhausen T
J Virol; 2021 Oct; 95(21):e0097521. PubMed ID: 34406858
[TBL] [Abstract][Full Text] [Related]
7.
Salleh MZ; Deris ZZ
Life (Basel); 2022 Feb; 12(2):. PubMed ID: 35207518
[TBL] [Abstract][Full Text] [Related]
8. Structural Basis of Covalent Inhibitory Mechanism of TMPRSS2-Related Serine Proteases by Camostat.
Sun G; Sui Y; Zhou Y; Ya J; Yuan C; Jiang L; Huang M
J Virol; 2021 Sep; 95(19):e0086121. PubMed ID: 34160253
[TBL] [Abstract][Full Text] [Related]
9. Strong Binding of Leupeptin with TMPRSS2 Protease May Be an Alternative to Camostat and Nafamostat for SARS-CoV-2 Repurposed Drug: Evaluation from Molecular Docking and Molecular Dynamics Simulations.
Ramakrishnan J; Kandasamy S; Iruthayaraj A; Magudeeswaran S; Chinnasamy K; Poomani K
Appl Biochem Biotechnol; 2021 Jun; 193(6):1909-1923. PubMed ID: 33512650
[TBL] [Abstract][Full Text] [Related]
10. Computational Identification of a Putative Allosteric Binding Pocket in TMPRSS2.
Sgrignani J; Cavalli A
Front Mol Biosci; 2021; 8():666626. PubMed ID: 33996911
[TBL] [Abstract][Full Text] [Related]
11. Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity.
Hoffmann M; Hofmann-Winkler H; Smith JC; Krüger N; Arora P; Sørensen LK; Søgaard OS; Hasselstrøm JB; Winkler M; Hempel T; Raich L; Olsson S; Danov O; Jonigk D; Yamazoe T; Yamatsuta K; Mizuno H; Ludwig S; Noé F; Kjolby M; Braun A; Sheltzer JM; Pöhlmann S
EBioMedicine; 2021 Mar; 65():103255. PubMed ID: 33676899
[TBL] [Abstract][Full Text] [Related]
12. In Silico Analysis and Synthesis of Nafamostat Derivatives and Evaluation of Their Anti-SARS-CoV-2 Activity.
Fujimoto KJ; Hobbs DCF; Umeda M; Nagata A; Yamaguchi R; Sato Y; Sato A; Ohmatsu K; Ooi T; Yanai T; Kimura H; Murata T
Viruses; 2022 Feb; 14(2):. PubMed ID: 35215982
[TBL] [Abstract][Full Text] [Related]
13. Virtual Screening of Natural Products against Type II Transmembrane Serine Protease (TMPRSS2), the Priming Agent of Coronavirus 2 (SARS-CoV-2).
Rahman N; Basharat Z; Yousuf M; Castaldo G; Rastrelli L; Khan H
Molecules; 2020 May; 25(10):. PubMed ID: 32408547
[TBL] [Abstract][Full Text] [Related]
14. Molecular docking analysis reveals the functional inhibitory effect of Genistein and Quercetin on TMPRSS2: SARS-COV-2 cell entry facilitator spike protein.
Manjunathan R; Periyaswami V; Mitra K; Rosita AS; Pandya M; Selvaraj J; Ravi L; Devarajan N; Doble M
BMC Bioinformatics; 2022 May; 23(1):180. PubMed ID: 35578172
[TBL] [Abstract][Full Text] [Related]
15. Molecular docking between human TMPRSS2 and SARS-CoV-2 spike protein: conformation and intermolecular interactions.
Hussain M; Jabeen N; Amanullah A; Baig AA; Aziz B; Shabbir S; Raza F; Uddin N
AIMS Microbiol; 2020; 6(3):350-360. PubMed ID: 33029570
[TBL] [Abstract][Full Text] [Related]
16. A quantum chemical study on the anti-SARS-CoV-2 activity of TMPRSS2 inhibitors.
Kondo A; Fujimoto KJ; Yanai T
Phys Chem Chem Phys; 2023 Aug; 25(30):20597-20605. PubMed ID: 37477571
[TBL] [Abstract][Full Text] [Related]
17. An Enzymatic TMPRSS2 Assay for Assessment of Clinical Candidates and Discovery of Inhibitors as Potential Treatment of COVID-19.
Shrimp JH; Kales SC; Sanderson PE; Simeonov A; Shen M; Hall MD
bioRxiv; 2020 Aug; ():. PubMed ID: 32596694
[TBL] [Abstract][Full Text] [Related]
18. Withanone and Withaferin-A are predicted to interact with transmembrane protease serine 2 (TMPRSS2) and block entry of SARS-CoV-2 into cells.
Kumar V; Dhanjal JK; Bhargava P; Kaul A; Wang J; Zhang H; Kaul SC; Wadhwa R; Sundar D
J Biomol Struct Dyn; 2022 Jan; 40(1):1-13. PubMed ID: 32469279
[TBL] [Abstract][Full Text] [Related]
19. Molecular mechanism of inhibiting the SARS-CoV-2 cell entry facilitator TMPRSS2 with camostat and nafamostat.
Hempel T; Raich L; Olsson S; Azouz NP; Klingler AM; Hoffmann M; Pöhlmann S; Rothenberg ME; Noé F
Chem Sci; 2021 Jan; 12(3):983-992. PubMed ID: 35382133
[TBL] [Abstract][Full Text] [Related]
20. An Enzymatic TMPRSS2 Assay for Assessment of Clinical Candidates and Discovery of Inhibitors as Potential Treatment of COVID-19.
Shrimp JH; Kales SC; Sanderson PE; Simeonov A; Shen M; Hall MD
ACS Pharmacol Transl Sci; 2020 Oct; 3(5):997-1007. PubMed ID: 33062952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
